Search | Clinical Trials Finder

Conditions: Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Placebo (PB); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Glendale, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 47
States / cities: Arcadia, California • Covina, California • Los Angeles, California + 37 more

Conditions: Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 61
States / cities: Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 48 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis
Interventions: Survodutide, Placebo matching survodutide; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 124
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 96 more

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions: Metabolic surgery, Incretin-Based Therapy; Procedure · Drug
Lead sponsor: Ali Aminian; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin Alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 43
States / cities: Arcadia, California • Covina, California • Los Angeles, California + 34 more

Conditions: NASH/MASH, NAFLD/MASLD
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 139
States / cities: Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: BIO89-100, Placebo; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 88
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 68 more

Conditions: Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions: ESG + lifestyle modification, Lifestyle modification; Device · Behavioral
Lead sponsor: Pichamol Jirapinyo, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Morgantown, West Virginia

Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: Miricorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions: Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B); Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 48
States / cities: Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 41 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: Miricorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Pegozafermin, Placebo; Biological · Other
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 141
States / cities: Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 122 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions: Pegozafermin, Placebo; Biological · Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 135
States / cities: Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 112 more

Conditions: MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Interventions: Thermoacoustic Enhanced Ultrasound; Device
Lead sponsor: Endra Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Interventions: TVB-2640, Placebo; Drug · Other
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 103
States / cities: Huntsville, Alabama • Madison, Alabama • Sun City, Arizona + 80 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 165
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 130 more

Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 161
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 135 more

Conditions: NASH With Fibrosis, MASH With Fibrosis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 200
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more

Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Rezdiffra; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: West Conshohocken, Pennsylvania

Conditions: NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
Interventions: Digoxin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Metabolic Dysfunction-associated Steatohepatitis
Interventions: Placebo, ECC4703, ECC0509; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 58
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 49 more

Conditions: NAFLD, NASH
Interventions: DD01, Placebo; Drug
Lead sponsor: Neuraly, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Maitland, Florida • Monroe, Louisiana • West Monroe, Louisiana + 8 more

Conditions: Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Interventions: Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications; Behavioral
Lead sponsor: Grand Valley State University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wyoming, Michigan

Search by objective public record fields.

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Fibrosis Lessens After Metabolic Surgery

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Evaluating the Pharmacokinetics and Safety of Miricorilant

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Thermoacoustic Method for Estimating Liver Fat Fraction

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Rezdiffra Pregnancy and Lactation Registry

Digoxin In NASH (CODIN)

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults